Choosing the right macrolide antibiotic: A guide to selection

Drugs

Volumn 53, Issue 3, 1997, Pages 349-357

  Charles, Lesley ^a   Segreti, John ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BORRELIA BURGDORFERI; BRONCHITIS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; HELICOBACTER PYLORI; HUMAN; LYME DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; MORAXELLA CATARRHALIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NAUSEA; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; REVIEW; SEXUALLY TRANSMITTED DISEASE; SINUSITIS; VERTIGO;

EID: 0030887794     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753030-00002     Document Type: Review

References (107)

1. Piscitelli S, Danziger L, Rodvold K. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-52
2. Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989; 33: 1419-22
3. Chu S-Y, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992; 36: 1147-50
4. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl. A: 73-82
5. Girard AE, Girard A, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987; 31: 1948-54
6. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1056-60
7. Bonnet M, Van der Auwera P. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother 1992; 36: 1302-9
8. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991; 35: 1186-90
9. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993; 37: 265-9
10. Tremblay D, Mignot A, Couraud L, et al. Concentrations of roxithromycin in lung tissue after repeat dosing. Br J Clin Pract 1988; 44 Suppl. 55: 64-6
11. Nilsen OG. Pharmacokinetics of macrolides: comparison of plasma, tissue and free concentrations with special reference to roxithromycin. Infection 1995; 23 Suppl. 1: 55-9
12. Hardy D, Hensey D, Beyer J, et al. Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710-9
13. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991; 27 Suppl. A: 1-9
14. Ednie LM, Visalli MA, Jacobs MR, et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 1950-2
15. Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicroh Agents Chemother 1986; 30: 865-73
16. Segreti J. In vitro activity of macrolides against intracellular Legionella pneumophila. Diag Microbiol Infect Dis 1996; 25: 123-6
17. Chin N-X, Neu NM, Labthavikul P, et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1987; 31: 463-6
18. Segreti J, Kessler HA, Kapell KS, et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob Agents Chemother 1987; 31: 100-1
19. Benson CA, Segreti J, Beaudette FE, et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 328-30
20. Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob Agents Chemother 1991; 35: 1524-6
21. Hardy D, Swanson RN, Rode R, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Hemophilus influenzae by 14 hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990; 34 (7): 1407-13
22. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 462-70
23. Perronne C, Gikas A, Truffot-Pernot C, et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 34: 1508-11
24. Fernandes PB, Hardy DJ, McDaniel D, et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-4
25. Gelber RH, Siu P, Tsang M, et al. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 760-3
26. Franzblau SG, Hastings RC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988; 32: 1758-62
27. Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 579-81
28. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989; 33: 1413-8
29. Brown BA, Wallace Jr RJ, Onyi GO. Activities of four macrolides including clarithromycin, against Mycobacterium fortuitum. Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36(1): 180-4
30. Hardy DJ, Hanson CW, Hensey DM, et al. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-6
31. Levin JM, Nelson JA, Segreti J, et al. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 1444-6
32. Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP 62.993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 1988; 32: 752-4
33. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 1939-47
34. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1993; 37: 1203-5
35. Edelstein PH, Edelstein MAC. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother 1991; 35: 180-1
36. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989; 33: 1614-6
37. Bermudez LEM, Young LS. Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor againsi Mycobacterium avium complex. Antimicrob Agents Chemolher 1988; 32: 1149-53
38. Inderlied CB, Kolonoski PT, Wu M, et al. In vitro and in vim activity of azithromycin (CP62,993) against the Mycobacterium avium complex. J Infect Dis 1989; 159: 994-7
39. Scieux C, Bianchi A, Chappey B, et al. In vitro activity of azithromycin against Chlamydia trachomatis. J Antimicrob Chemother 1990; 25: 7-10
40. Counter FT, Ensminger PW, Preston DA, et al. Synthesis and antimicrobial evaluation of dirithromycin (AS-# 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother 1991; 35: 1116-26
41. Yu K-W, Neu HC. In vitro activity of dirithromycin ( LY 237216) compared with activities of other macrolide antibiotics. Antimicroh Agents Chemother 1990; 34: 1839-42
42. Segreti J, Kapell KS. In vitro activity of dirithromycin against Chlamydia trachomatis. Antimicrob Agents Chemother 1994; 38: 2213-4
43. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91 Suppl. 3A: 40-5
44. Levenstein JH. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother 1991; 27 Suppl. A: 67-74
45. Bachand RT. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with Streptococcal pharyngitis. J Antimicrob Chemother 1991; 27 Suppl. A: 75-82
46. Gillum JG, Israel DS, Scott RB, et al. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1996; 40: 1715-6
47. Lindstrom TD, Haussen BR, Wrighton SA. Cytochrome P450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993; 37: 265-9
48. Lode HC. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10: 807-12
49. Clarithromycin and azithromycin. Med Lett 1992; 34 (870): 45-7
50. Wallace RJ, Brown BA, Griffith DE. Drug intolerance to high dose clarithromycin among elderly patients. Diag Microbiol Infect Dis 1993; 16: 215-21
51. Vance K, Watson-Bitar M, Gustavson L, et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995; 39: 1355-60
52. Chave J-P, Munafo A, Chatton J-Y, et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother 1992; 36: 1013-8
53. Pichichero M, Margolis P. A comparison of cephalosporins and penicillins in the treatment of Group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991; 10: 275-81
54. Derriennic M, Conforti PM, Sides GD. Dirithromycin in the treatment of streptococcal pharyngitis. J Antimiciob Chemother 1993; 31 Suppl. C: 89-95
55. Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991; 91: 23S-6S
56. Karma P, Pukunder J, Perittila M, et al. The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1990; 27 Suppl. A: 83-90
57. Casiano RR. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991; 91 Suppl. 3A: 27S-30S
58. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1993; 31: 137-46
59. Pukander JS, Jero JP, Kaprio EA, et al. Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993; 12: S118-21
60. McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12 Suppl. 3: S122-7
61. Gooch WM, Gan VN, Corder WI. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12 Suppl. 3: S128-33
62. Girard AE, Cimochowski CR, Faiella JA. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections. J Antimicrob Chemother 1993; 31 Suppl. E: 29-37
63. Ramet J. A comparative safety and efficacy of clarithromycin and azithromycin in the short course treatment of children with acute otitis media [abstract no. 10.9]. Third International Conference on the Macrolides, Azalides and Streptogramins: 1996 Jan 24-26: Lisbon
64. Arguedas AG, Loaiza C, Rodriguez F, et al. Comparative trial of azithromycin versus clarithromycin in the treatment of children with acute otitis media with effusion [abstract no. 10.10]. Third International Conference on the Macrolides, Azalides and Streptogramins: 1996 Jan 24-26: Lisbon
65. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of paediatric patients with acute otitis media. Third International Conference on the Macrolides, Azalides and Streptogramins: 1996 Jan 24-26: Lisbon
66. Alper CM, Doyle WJ, Seroky JT, et al. Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla. Antimicrob Agents Chemother 1996; 40: 1889-92
67. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infection. Am J Med 1991; 91 Suppl. 3A: 31-5
68. Aidons PM. A comparison of clarithromycin and ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicroh Chemother 1991; 27 Suppl. A: 101-8
69. Mertens JC, van Barneveld PWC, Asm HRG, et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1992; 36: 1456-9
70. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community acquired pneumonia. J Antimicrob Chemother 1991; 27 Suppl. A: 117-24
71. Hoepelman AIM, Sips AP, van Helmond JLM, et al. A single-blind comparison of three-day azithromycin and ten-day coamoxiclav treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1993; 31: 147-52
72. Myburgh J, Nagel GJ, Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993; 31: 163-9
73. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicroh Chemother 1993; 31 Suppl. E: 153-62
74. Hamedani P, Ali J, Hafeez S, et al. The safety and efficacy of clarithromycin in patients with Legionella pneumonia. Chest 1991; 100: 1503-6
75. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaire's disease. J Antimicrob Chemother 1993; 31: 171-6
76. Strle F, Preac-Mursic V, Cimperman J, et al. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 1993; 21: 83-8
77. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline, and phenoxymethyl-penicillin. J Antimicrob Chemother 1992; 30: 543-50
78. Weber K, Wilske B, Preac-Mursic V, et al. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993; 21: 367-72
79. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91
80. Alder J, Mitten M, Jarvis K, et al. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother 1993; 37: 1329-33
81. Demarco CC. Clarithromycin and ils use in the treatment of late stage Lyme disease [abstract no, 1.12]. Third International Conference on the Macrolides, Azalides, and Streptogramins: 1996 Jan 24-26: Lisbon
82. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob Agents Chemother 1996; 40: 468-9
83. Steingrimsson O, Olafsson JH, Thorarinsson H, et al. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25 Suppl. A: 109-14
84. Lauraranta J, Saarinen K, Mustonen M, et al. Single dose oral azithromycin versus seven day doxycycline in the treatment of non-gonococcal urethritis in males. J Antimicrob Chemother 1993; 31 Suppl. E: 177-83
85. Martin D, Mroczkowski TF, Dalu T, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327: 921-5
86. Handsfield HH, Siegal NA, Verdon MS. Single dose azithromycin vs. ceftriaxone for treatment of uncomplicated gonorrhea. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy: 1991 Sep 30: Chicago
87. Nuovo J, Melnikow J, Paliescheskey M, et al. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Clamydia trachomatis cervicitis. J Am Board Fam Pract 1995; 8: 7-16
88. Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124: 389-99
89. Glupczynski Y, Burette A. Failure of azithromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol 1990; 85: 98-9
90. Logan RP, Gummett PA, Schaufelberger HO, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35: 323-6
91. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med 1996; 100: 42S-51S
92. Vakil N, Fennerty B. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med 1996; 100: 60S-4S
93. O'Brien B, Goeree R, Mohamed AH, et al. Cost-effectiveness ofHelicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64
94. Imperiale TF, Speroff T, Cebul RD, et al. A cost analysis of alternative treatment for duodenal ulcer. Ann Intern Med 1995; 123: 665-72
95. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8
96. Benson CA. Treatment of disseminated disease due to Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1994; 18 Suppl. 3: 237-42
97. Inderlied CB, Kolonoski PT, Wu M, et al. Amikacin, ciprofloxacin and imipenem treatment for disseminated Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 176-80
98. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989; 33: 1614-6
99. Dautzenberg B, Tuffot C, Legris S, et al. Activity of Clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1991; 144: 564-9
100. Barradell LB, Plosker GL, McTavish D. Clarithromycin: a review of its pharmacological properties and therapeutic efficacy in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome. Drugs 1993; 46 (2): 289-312
101. Dautzenberg B, Saint Mare T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Int Med 1993; 153 (3): 368-72
102. Young LS, Wiviott L, Wu M, et al. Azithromycin for treatment of Mycobacterium avium intracellulare complex infections in patients with AIDS. Lancet 1991; 338: 1107-9
103. Shafrin SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and Clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-83
104. Pierce M, Crampton S, Henry D, et al. A randomized trial of Clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-91
105. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392-8
106. Wallace Jr RJ, Tanner D, Brennan PJ, et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Int Med 1993; 119: 482-6
107. Ji B, Jamet P, Perani EG, et al. Powerful bactericidal activities of Clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993; 168: 188-90